Prevalence of neutralising antibodies against SARS-CoV-2 in acute infection and convalescence: A systematic review and meta-analysis.

BACKGROUND: Individuals infected with SARS-CoV-2 develop neutralising antibodies. We investigated the proportion of individuals with SARS-CoV-2 neutralising antibodies after infection and how this proportion varies with selected covariates. METHODOLOGY/PRINCIPAL
FINDINGS: This systematic review and meta-analysis examined the proportion of individuals with SARS-CoV-2 neutralising antibodies after infection and how these proportions vary with selected covariates. Three models using the maximum likelihood method assessed these proportions by study group, covariates and individually extracted data (protocol CRD42020208913). A total of 983 reports were identified and 27 were included. The pooled (95%CI) proportion of individuals with neutralising antibodies was 85.3% (83.5-86.9) using the titre cut off >1:20 and 83.9% (82.2-85.6), 70.2% (68.1-72.5) and 54.2% (52.0-56.5) with titres >1:40, >1:80 and >1:160, respectively. These proportions were higher among patients with severe COVID-19 (e.g., titres >1:80, 84.8% [80.0-89.2], >1:160, 74.4% [67.5-79.7]) than those with mild presentation (56.7% [49.9-62.9] and 44.1% [37.3-50.6], respectively) and lowest among asymptomatic infections (28.6% [17.9-39.2] and 10.0% [3.7-20.1], respectively). IgG and neutralising antibody levels correlated poorly.
CONCLUSIONS/SIGNIFICANCE: 85% of individuals with proven SARS-CoV-2 infection had detectable neutralising antibodies. This proportion varied with disease severity, study setting, time since infection and the method used to measure antibodies.

Introduction

The emergence of Coronavirus Disease 2019 (COVID-19), caused by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), in December 2019 [1] marked the start of the first global pandemic of this century, resulting in over 34 million cases and 1 million deaths in the following six months [2]. SARS-CoV-2 infection has a wide spectrum of manifestations ranging from asymptomatic infections to a multi-system disease with multi-organ involvement and a high mortality [3]. Its diagnosis is based on the detection of viral RNA using Reverse Transcription Polymerase Chain Reaction (RT-PCR) or rapid antigen tests [4]. SARS-CoV-2 specific assays to detect immunoglobulins (Ig) G, M, and A are well established and individuals with anti-SARS-CoV-2 antibodies are expected to have some degree of protection against infection [5]. However their correlation to functional immunity is poorly described [6].

Functional immunity is better depicted by measuring neutralising antibodies, which bind to viral surface proteins, and prevent cell infection and plaque formation in cell cultures [7]. There is however a wide array of methodologies to measure neutralising antibodies, from employing microscopy to measuring cell metabolism in the presence of virus and antibody. In addition, reporting measures differ between studies, some plot a sigmoid curve and report the viral titres that reduce viral plaques or cell metabolism to 50%, and others report the minimum antibody titre that abolishes all viral activity in cell culture.

Here we present a systematic review and meta-analysis to describe the proportion of individuals who develop SARS-CoV-2 neutralising antibodies after infection, whether this proportion varies with disease severity, the time after symptoms onset, and the correlation between IgG and neutralising antibodies titres.

Methods

This study followed the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines [8]. Institutional review board approval and informed consent were not required because all data were obtained from secondary data sources and were de-identified. Similarly, the study used secondary sources of data and was not possible to seek public and patient involvement. The study protocol was registered at PROSPERO (CRD42020208913).

Search strategy and selection criteria

We conducted a systematic search of publications using the PubMed (including MEDLINE), Web of Science, and Cochrane databases, and of preprints in bioRxiv, medRxiv and the Collabovid.org website, which includes a compilation of manuscripts on COVID-19 from arXiv, bioRxiv, Elsevier and medRxiv. The search included reports from 1st January 2020 to 12th August 2020 and was limited to human studies. The search terms used were: “severe acute respiratory coronavirus 2” OR “SARS-CoV-2” OR “sars AND virus” OR “sars AND cov” OR “COVID-19” OR “COVID 2019” OR “novel coronavirus” OR “new coronavirus” OR “Wuhan coronavirus” OR “Coronavirus disease 19” OR “2019-nCoV” AND “neutralising antibod*” OR “neutralizing antibod*” OR “neutralising AND antibod*” OR “neutralizing AND antibod*”, without language restrictions (S1 Table). Two reviewers (HRS and TE) independently screened the titles and abstracts and selected full text manuscripts to assess for inclusion. Studies were retained if they had tested for neutralising antibodies against SARS-CoV-2 in participants with laboratory confirmed SARS-CoV-2 infection. We included studies that reported aggregated or individual data or where data could be extracted from graphical displays. We excluded studies without original data, if data could not be extracted, or if the titre cut offs used were not comparable to other studies. Studies including SARS-CoV-2 vaccinated patients or individuals receiving plasma therapy were excluded.

Data extraction and bias assessment

Data were extracted using a pre-piloted extraction form, including author, year, country, study design, setting (hospital, community or plasma donor), age, gender, severity of symptoms (asymptomatic, mild, moderate, severe), and weeks/months elapsed since infection. Laboratory data included the assay used to measure neutralising antibodies, the plaque reduction threshold used to classify participants as having neutralising antibodies, the lower threshold attained, additional titre thresholds used, and the IgG Enzyme linked immunoassay (ELISA) used. Data were extracted from digitised graphs using Engauge software for individual data extraction (http://markummitchell.github.io/engauge-digitizer/). Data were selected using a 50% plaque reduction cut off for neutralising antibody titres (i.e., 50% of the virus in the culture was neutralised by the patient’s serum (PRNT50)) or the PRNT90 for one study in which the PRNT50 was not provided. Immunoglobulins usually increase on week after infection and peak after 21 days. Thus, for studies that described a time window for sample collection (i.e., 7–10 days) we recorded the end of the window to generate the most conservative estimate. We extracted data for titre cut offs 1:20, 1:40, 1:80, and 1:160, as these were the dilutions used by most studies.

The NIH Study Quality Assessment tool was used to assess the risk of bias and study quality for case series and cohort studies (https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools). Studies were initially rated as having good, fair, or poor quality, and ratings were discussed to reach consensus.

Data analysis

We developed three statistical models in an R software environment to assess 1) the combined proportion of individuals with neutralising antibodies across studies; 2) the correlation between the proportions of participants with IgG and neutralising antibodies and 3) the correlation between individual-level IgG and neutralising antibodies. The meta-analysis combined the proportion of participants with neutralising antibodies across all studies. We used the maximum likelihood method with a quasi-Monte Carlo approximation. Ten thousand samples were simulated using the inverse transformation method by conditioning on different variables that could modify the proportion positive, including disease severity, participant recruitment setting, and neutralising antibody detection method. The resulting proportions were summarised as means and 95% confidence intervals. The correlation between the proportions of participants in a study with IgG and neutralising antibodies was estimated using a quasi-Monte Carlo method for maximum likelihood estimation, adjusting for study setting, titre cut off threshold, and neutralising antibody detection method. The 95% confidence intervals were obtained via parametric bootstraps. The individual correlation model was a bivariate model of individually extracted IgG and neutralising antibody data. Each study was modelled separately because studies used different ELISA and reporting units and did not provide enough background to standardise results. The model was fitted using a maximum likelihood method, with covariates taken from each study. A more detailed description of the statistical methods is available in the supporting information (S1 Text).

Results

The search identified 983 reports. After screening titles and abstracts 78 full-text articles were assessed for eligibility, resulting in 27 studies that met the criteria for inclusion in the analysis (Fig 1). Twelve studies were case series and fifteen cohort studies, as shown in Table 1. Seventeen studies were conducted in hospital settings, three in community or outreach centres, and seven were based on plasma donors. Thirteen studies included hospitalised and eleven convalescent patients. Only one study included children. IgG was assessed using eleven in-house and 16 commercial ELISAs. Neutralising antibodies were detected using the Focus Reduction Neutralisation Test (FRNT) by two studies, the PRNT by five studies, the Virus Neutralisation Test (VNT) by three studies, the surrogate VNT by one study, the pseudovirus VNT by nine studies and the microneutralisation method by seven studies.

Fig 1

Flow diagram of study selection.

Table 1

Study characteristics of the 27 studies included.

Author	Country	Study design	Setting	Participants	Disease Severity*	IgG Assay*	Target	Neutralising Antibody method	Sample size
Brochot et al	France	Cohort	H	Inpatient	M/S	ELISA IH	S1, S2, N, RBD	Pseudovirus VNT	30
Tang et al	USA	Cohort	H	Inpatient	M/S	EuroimmunRocheAbbott	S1SN	FRNT	48
Kohmer et al	Germany	Case series	H	Inpatient	M/S	EuroimmunVircell	S1S, N	PRNT	45
Bonelli et al	Italy	Cohort	H	Inpatient/Community	M/S	Diasorin	S1, S2	Microneutralisation	304
Kohmer,Westhaus et al	Germany	Case series	H	Inpatient	S	AbbottVirotechVircell	NNN	PRNT	33
Suhandynata et al	USA	Cohort	C	Convalescent	A	AbbottRocheDiazyme	NN, Sn/a	Pseudovirus VNT	63
Zhang et al	China	Case series	H	Convalescent	M/S	ELISA IH1IH2	S1S2	Pseudovirus VNT	67
Stromer et al	Germany	Case series	PD	Convalescent	M/Md/S	AbbottRocheDyazymeMikrogenEpitope diagnosticsEuroimmun	NNN, SNNS1	PRNT	26
Liu et al	China	Case series	H	Paediatric	M/S	n/a	n/a	Pseudovirus VNT	9
Crawford et al	USA	Cohort	H/C	Convalescent	A/M/Md	ELISA IH1IH2	S	Psuedovirus VNT	34
Juno et al	Australia	Cohort	unstated	Convalescent	M	ELISA IH1IH2	SRBD	Microneutralisation	41
Wang et al	China	Cohort	H	Inpatient	M/S	ELISA IH1IH2IH3IH4IH5	S1S2NRBDS	Pseudovirus VNT	23
Zeng et al	USA	Cohort	H	Inpatient	M/M	Epitope diagnostics	N	PseudovirusVNT	55
Ko et al	South Korea	Cohort	H	Inpatient	A	PCL	N, S	Microneutralisation	15
Ruetalo et al	Germany	Case series	PD	Community	A/M	EuroimmunMediagnostRoche	S1RBDN	VNT	49
Lee et al	USA	Cohort	PD	Convalescent	A/Md/Md/S	ELISA IH	RBD	PRNT	149
Wu et al	China	Case series	H	Inpatient	M	ELISA IH1IH2IH3	RBDS1S2	Pseudovirus VNT	175
Bosnjak et al	Germany	Cohort	H	Inpatient	M	Euroimmun	S1	Surrogate VNT	40
Jaaskelainen et al	Finland	Case series	PD	Convalescent	M/Md/S	EuroimmDiasorinAbbott	S1S1, S2n/a	Microneutralisation	70
Percivalle et al	Italy	Cohort	PD	Convalescent	A/M/Md/S	n/a	n/a	Microneutralisation	38
Suthar et al	USA	Case series	H	Inpatient	M/Md	ELISA IH	RBD	FRNT	44
Zettl et al	Germany	Cohort	H	Inpatient	M/Md/S	Euroimmun	S1	VNT	25
Salazar et al	USA	Cohort	PD	Convalescent	M/Md/S	ELISA IH	S	Microneutralisation	68
Klein et al	USA	Case series	PD	Convalescent	M/Md	EuroimmunELISA IH1IH2	S1SRBD	Microneutralisation	126
Padoan et al	Italy	Cohort	H	Convalescent	M/Md/S	AbbottRocheDIESSEOrtho Clinical Dxs	NNNative antigenS	PRNT	52
Gozalbo et al	Spain	Case series	Hospital	Inpatient	Md/S	ELISA IH	RBD	Pseudovirus VNT	51
Mueller et al	Germany	Case series	Community	Community	M	EuroimmunDiasorinAbbottRoche	S1S1, S2NN	VNT	34

*A = asymptomatic, M = mild, Md = Moderate, S = severe; IH = in house; hospital = H, Community = C, Plasma donor = PD; Bold = ELISA individual data extracted

The risk of bias in the studies is shown in the supporting information (S2 Table). The main risk identified was the lack of sample size estimations, as only two studies included pre-study sample size estimations, and sample sizes were usually based on the number of cases or samples available. None of the studies reported blinding of the endpoints. Four studies were considered to have fair and 23 to have good study quality.

Proportion of participants with SARS-CoV-2 neutralising antibodies

Eighteen studies reported the proportion of participants with SARS-CoV-2 neutralising antibodies with titres >1:20 [9-26], 18 reported titres >1:40 [9-12,14,16,17,19-22,25,27-32],17 reported titres >1:80 [9-12,14,16,17,19-22,25,27,29,33-35], and 18 reported titres >1:160 [9-12,14-17,19-22,25,27,29,32-34]. The pooled proportion of participants with neutralising antibodies varied with the titre threshold used (Fig 2) and ranged from 85.3% (95%CI 83.5 to 86.9) in studies using threshold titres >1:20; 83.9% (95%CI 82.2 to 85.6) with titres >1:40, and 70.2% (95%CI 68.1 to 72.5) and 54.2% (52.0 to 56.5) with titres >1:80 and >1:160, respectively (Table 2).

Fig 2

Estimated pooled proportion (95% confidence interval) of participants with neutralisation antibodies by titre cut-off and time.

Table 2

Estimated proportion of participants with neutralising antibodies with titre cut off > 1:20, 1:40, 1:80 and 1:160 by timepoints and selected covariates.

	Cut off >20	Cut off >40	Cut off >80	Cut off >160
Variables	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)
Any time
Overall	85.3 (83.5–86.9)	83.9 (82.2–85.6)	70.2 (68.1–72.5)	54.2 (52.0–56.5)
Severity
Asymptomatic	14.4 (2.3–35.4)	97.9 (89.1–100.0)	28.6 (17.9–39.2)	10.0 (3.7–20.1)
Mild	81.2 (76.5–85.3)	79.3 (74.2–84.2)	56.7 (49.9–62.9)	44.1 (37.3–50.6)
Mixed–excluding severe	93.2 (85.1–97.9)	87.1 (76.1–94.5)	68.9 (59.6–77.9)	53.1 (40.7–64.9)
Mixed–including severe	92.8 (88.6–96.2)	76.8 (72.9–80.2)	88.0 (84.3–91.2)	62.6 (57.7–68.5)
Moderate	82.3 (70.5–90.7)	86.1 (79.5–91.1)	73.6 (62.1–82.4)	57.6 (47.1–67.4)
Severe	89.3 (83.7–93.6)	90.0 (85.0–94.0)	84.8 (80.0–89.2)	74.4 (67.5–79.7)
Unknown	76.4 (57.0–90.1)	–	–	–
Setting
Community	63.4 (57.6–70.0)	85.7 (80.6–89.9)	53.5 (46.6–60.2)	45.5 (39.9–52.4)
Plasma donor	78.9 (75.3–82.1)	66.8 (62.5–71.4)	66.0 (61.8–70.1)	41.1 (36.8–46.3)
Hospital	93.4 (91.0–95.1)	88.9 (86.7–90.9)	75.1 (72.7–78.2)	61.9 (58.9–64.8)
Hospital/Community	93.6 (86.9–98.2)	–	–	65.4 (57.8–89.6)
Not stated	–	98.3 (91.9–100.0)	–	–
Method
VNT	76.8 (72.4–80.6)	81.3 (76.1–85.7)	54.3 (49.3–58.7)	43.4 (37.8–48.7)
Surrogate VNT	96.0 (90.8–98.7)	–	–	–
Microneutralisation	74.6 (69.5–79.1)	72.3 (68.6–75.8)	53.9 (49.4–58.3)	31.5 (27.4–35.8)
FRNT	95.1 (92.1–97.4)	95.5 (91.5–98.1)	88.4 (80.1–94.2)	79.0 (72.3–84.8)
PRNT	82.6 (77.2–87.6)	86.2 (82.8–90.3)	74.7 (69.6–82.9)	59.1 (54.2–65.5)
Pseudovirus	95.0 (91.0–97.5)	95.0 (91.6–97.3)	86.1 (82.7–89.0)	43.4 (37.8–48.5)
Month 1
Overall	86.4 (82.8–89.2)	80.9 (77.6–84.1)	68.3 (64.6–72.2)	60.7 (55.8–65.1)
Severity
Asymptomatic	–	–	–	–
Mild	77.3 (67.7–86.0)	70.7 (60.7–80.3)	54.1 (40.4–65.3)	50.3 (38.4–61.6)
Mixed–excluding severe	90.8 (77.7–98.0)	87.5 (62.2–99.4)	66.3 (35.1–90.7)	65.5 (33.9–89.3)
Mixed–including severe	93.7 (88.9–97.4)	88.0 (79.1–95.0)	72.6 (62.0–81.2)	61.6 (53.9–74.2)
Moderate	80.5 (70.7–90.2)	74.1 (65.0–83.5)	67.3 (58.2–77.2)	58.1 (50.7–66.8)
Severe	81.9 (65.6–90.2)	79.0 (69.6–87.2)	70.5 (62.1–79.1)	65.0 (46.8–74.6)
Unknown	–	–	–	–
Setting
Community	98.3 (92.9–100)	98.8 (93.4–100.0)	97.7 (90.2–100.0)	97.6 (90.1–100.0)
Plasma donor	66.9 (55.0–75.2)	53.8 (45.2–61.8)	33.9 (26.1–42.4)	39.1 (29.7–46.6)
Hospital	92.5 (89.1–95.1)	90.0 (86.0–93.3)	77.8 (72.5–82.4)	70.6 (64.2–76.3)
Hospital/Community	93.8 (87.8–97.9)	–	–	–
Method
VNT	–	–	54.1 (40.2–69.4)	–
Surrogate VNT	–	–	–	–
Microneutralisation	66.8 (55.0–75.2)	53.8 (45.2–61.8)	33.9 (26.1–42.4)	32.7 (20.5–41.4)
FRNT	94.0 (90.7–96.7)	93.4 (88.5–96.8)	81.0 (72.5–87.7)	68.6 (59.8–76.2)
PRNT	84.6 (75.3–92.2)	84.6 (75.1–91.9)	78.5 (68.5–87.3)	65.6 (58.3–76.7)
Pseudovirus	94.9 (90.2–98.0)	92.0 (86.0–96.5)	84.8 (77.5–90.6)	80.4 (71.6–87.7)
Month 2
Overall	81.5 (76.3–85.6)	92.6 (88.5–95.1)	57.5 (53.4–62.7)	61.6 (57.4–65.2)
Severity
Asymptomatic	–	–	19.0 (4.4–41.7)	6.9 (0.3–22.5)
Mild	66.2 (53.5–78.5)	87.7 (81.1 to 93.3)	48.4 (39.1–57.9)	25.8 (18.1–34.8)
Mixed–excluding severe	97.3 (91.6–99.9)	97.9 (92.3 to 99.9)	91.8 (82.3–97.6)	75.4 (62.8–85.8)
Mixed–including severe	88.0 (70.6–95.4)	88.7 (73.0 to 94.6)	64.3 (60.3–68.1)	77.7 (71.0–83.5)
Moderate	74.0 (56.4–86.5)	92.6 (77.8 to 99.6)	85.6 (57.1–99.2)	48.9 (17.0–79.5)
Severe	75.3 (65.1–84.9)	96.7 (90.0 to 99.7)	75.4 (61.7–89.3)	77.2 (64.6–88.3)
Unknown	–	–	–	–
Setting
Community	–	–	–	–
Plasma donor	71.8 (64.1–78.8)	87.2 (77.6–93.7)	56.0 (49.2–60.8)	70.4 (61.9–77.7)
Hospital	87.3 (80.4–91.9)	91.8 (85.7–94.8)	57.9 (52.8–64.7)	58.7 (53.6–62.9)
Hospital/Community	–	–	–	–
Not stated	–	98.5 (93.2–100.0)	–	–
Method
VNT	–	–	4.5 (0.6–12.1)	–
Surrogate VNT	–	–	–	–
Microneutralisation	71.8 (64.1–78.8)	93.7 (88.6–96.9)	52.8 (47.3–57.9)	37.3 (30.0–44.2)
FRNT	77.3 (54.8–90.9)	94.7 (75.9–100.0)	40.0 (28.1–52.0)	80.7 (60.3–93.0)
PRNT	86.3 (78.1–92.6)	73.3 (64.2–81.7)	64.5 (59.4–69.6)	71.6 (66.4–76.8)
Pseudovirus	93.7 (90.0–96.9)	97.5 (93.8–99.3)	79.5 (70.0–95.3)	73.9 (68.9–8.3)

The proportion of participants classified as having neutralising antibodies varied with the detection method, with the pseudovirus method reporting the highest and the microneutralisation method the lowest proportion of participants detectable (titre threshold >1:20, 94.9% [95%CI 90.2 to 98.0] and 66.8% [95%CI 55.0 to 75.2], respectively), with similar differences reported at all titre cut-offs (Table 2). The pooled proportion positive varied with disease severity (Fig 3). Studies focusing on severe COVID-19 reported higher proportions with neutralising antibodies than studies focusing on mild COVID-19, especially if they had used titre thresholds >1:80 (84.8% [95%CI 80.0 to 89.2] and 56.7% [95%CI 49.9 to 62.9], for severe and mild COVID-19, respectively) or >1:160 (74.4% [95%CI 67.5 to 79.7] and 44.1% [95%CI 37.3 to 50.6], respectively). Similarly, the proportion of patients testing positive was lower in studies of asymptomatic infections (14.4% with a titre threshold >1:20 [95%CI 2.3 to 35.4]; 97.1% with a titre >1:40 [one study, 95%CI 89.1 to 100], 28.6% with >1:80 [95%CI 17.9 to 39.2] and 10.0% [3.7 to 20.1] with >1:160). These associations were reflected in studies recruiting patients in hospitals, which had higher proportions of participants with neutralising antibodies than those recruiting among plasma donors or the community (titres >1:20: 93.4% [95%CI 91.0 to 95.1] compared with 78.9% [95%CI 75.3 to 82.1] and 63.4% [95%CI 57.6 to 70.0], respectively).

Fig 3

Estimated proportion positive (95% confidence interval) by disease severity, titre cut-off and time.

Studies reporting the proportion of patients with neutralising antibodies one and two months after infection were analysed separately to assess the effect of time on the development of antibias during the early stages after infection. The pooled proportion with neutralising antibodies among plasma donors was higher in month two than in month one although this was not statistically significant for most thresholds (Table 2). In contrast, in studies recruiting from hospital settings, the proportion of participants with neutralising antibodies was higher in month two at titres > 1:80 (77.8% [95%CI 72.5 to 82.4] to 57.9% [95% CI 52.8 to 64.7], >1:160 70.6% [95%CI 64.2 to 76.3] to 58.7% [95%CI 53.6 to62.9]). The pooled prevalence one and two months after infection had the same overall pattern, with the proportions being higher among participants with severe than mild COVID-19 (Table 2). The proportion positive in month two was lowest with the microneutralisation method than with the FRNT, PRNT and pseudovirus methods at titres >1:160 (37.3% [95%CI 30.0 to 44.2]; 80.7% [95%CI 60.3 to 93.0], 71.6% [95%CI 66.4 to 76.8] and 73.9% [95%CI 68.9 to 78.3], respectively).

Correlation of neutralising and IgG antibodies

The modelled correlation between the aggregate proportion of patients with measurable IgG against SARS-CoV-2 and neutralising antibodies was very low (0.055, corresponding to poor correlation). The estimate was not modified by the assays, titre cut-offs used or the study setting (Table 3). The correlation between individual IgG and neutralising antibodies ranged from 0.16 to 0.756 across the studies (Table 4 and Fig 4). The correlation between individual values was higher than the correlation of aggregated data, but there was a high variability across studies, as shown in Fig 5. We were unable to explore whether the IgG ELISA or neutralising method used modified the correlations as each study used a unique set of IgG and neutralisation methods. In five of six studies reporting disease severity [9-11,19,21,25], there was an increased correlation between IgG and neutralising antibodies with increasing disease severity [10,11,19,21,25].

Table 3

Maximum likelihood estimates (95% confidence interval) of the bivariate binomial mixed model.

The estimates for the intercept, titre cut off, setting and method are reported on the log-odds scale.

Covariate	Immunoglobulin G	Neutralizing antibodies
Intercept	5.398 (0.502 to 7.726)	2.903 (0.206 to 5.112)
Titre cut off	0.003 (-0.002 to 0.029)	-0.003 (-0.008 to 0.003)
Setting (ref. “Community”)
Hospital	-1.640 (-4.051 to 0.122)	-0.298 (-1.874 to 1.305)
Not stated	18.936 (0.334 to 56.965)	1.401 (-0.957 to 4.611)
Plasma donor	-1.658 (-3.996 to 0.137)	-1.163 (-2.994 to 0.574)
Method for nAB (ref. “FRNT”)
Microneutralisation	-0.504 (-2.220 to 1.230)
PRNT	-0.782 (-2.436 to 0.757)
Pseudovirus	0.639 (-2.176 to 0.820)
VNT	-0.472 (-2.256 to 1.373)
Random effects
Variance	3.762 (0.217 to 5.001)
Correlation	0.055 (4.793x10-9 to 0.500)

Table 4

Maximum likelihood estimates of the correlation of IgG and neutralising antibody titres (nAB).

Estimates reported in a log-odds scale with 95% confidence intervals.

Study	Correlation Estimate (95% Confidence intervals)
Ruetalo et al	0.727 (0.561 to 0.848)
Kohmor et al	0.589 (0.383 to 0.768)
Zettl et al	0.16 (0.01 to 0.776)
Severity (Baseline = Mixed without severe)	IgG: Severe 1.094 (0.491 to 1.697)
	nAB: Severe 2.363 (1.66 to 3.066)
Suthar et al	0.756 (0.589 to 0.87)
Jaaskaleinen et al	0.375 (0.155 to 0.662)
Severity (Baseline = Mild)	IgG: Moderate -0.669 (-1.55 to 0.211)
	IgG: Severe -0.608 (-1.545 to 0.33)
	nAB: Moderate -0.897 (-1.772 to -0.022)
	nABs: Severe -0.693 (-1.625 to 0.239)
Zhang et al	0.652 (0.503 to 0.776)
Severity (Baseline = Mixed without severe)	IgG: Severe 0·973 (0.321 to 1.626)nAB: Severe 1.141 (0.611 to 1.67)
Salazar et al	0.51 (0.356 to 0.661)
Severity (Baseline = Mild)	IgG: Severe 1.549 (0.919 to 2.179)
	nAB: Severe 1.401 (0.676 to 2.127)
Mueller et al	0.723 (0.53 to 0.858)
Severity (Baseline = Asymptomatic)	IgG: Mild 1.023 (0.275 to 1.771)
	nAB: Mild 2.543 (1.232 to 3.853)
Wang et al	0.597 (0.431 to 0.743)
Severity (Baseline = Mild)	IgG: Severe 0.564 (0.12 to 1.008)
	nAB: Severe 1.067 (0.614 to 1.521)

IgG: immunoglobulin G. nABs: neutralising antibodies.

Fig 4

Estimated correlation (95% confidence interval) of individual IgG and neutralising antibodies by study.

Fig 5

Scatterplot of individual neutralising and IgG antibody values by study.

Discussion

Despite major efforts to understand the mechanisms for immunity after COVID-19, this is the first comprehensive systematic review synthesising the proportion of individuals who exhibit neutralising antibodies after natural SARS-CoV-2 infection. Although 85% of participants with previous SARS-CoV-2 infection had detectable neutralising antibodies, there was a wide variation across studies, which was partly explained by the method and cut off titres used. Studies using the microneutralisation and the pseudovirus methods reported the lowest and highest proportion of participants with neutralising antibodies, respectively, while studies using low titre cut offs (i.e., >1:20 and >1:40) reported a higher proportion of participants as having neutralising antibodies than those using higher titre cut offs (i.e., >1:80 and >1:160).

The proportion of participants with neutralising antibodies varied with study setting, COVID-19 severity, and time since infection. Studies on severe COVID-19 reported higher proportions of patients with neutralising antibodies than studies focusing on mild and moderate COVID-19, with studies on asymptomatic infections having the lowest proportion of patients with antibodies. Similarly, hospital-based studies reported higher proportions of participants with neutralising antibodies than studies based in the community or plasma donors, suggesting the study setting is a surrogate marker for disease severity. The lack of neutralising antibodies in a small but significant group of patients seen in this review might be explained by some patients having responses confined to SARS-CoV-2 antigens not identified by the assays used, or mediated through T cells, which are not detected by the neutralisation assays in this meta-analysis. Mild infections may also elicit responses that are restricted to the mucosal cells, where defence responses are dominated by the secretory immune system [36].

Only a subset of studies reported the pooled proportion of neutralising antibodies one and two months after infection. The proportion of participants with neutralising antibodies in the second month was slightly higher among plasma donors and slightly lower among patients recruited from hospital. However, the differences were small and confidence intervals overlapped. As neutralising antibodies peak within 21 days after symptoms onset, and symptoms onset if often poorly documented, it may be that the one-month timepoint is not ideal to demonstrate differences over time [37].

Surprisingly, the correlation between the detection of IgG and neutralising antibodies at study level was low, with a better correlation for the subset of studies with individual data. This is not surprising, as the correlation of aggregate data is necessarily a less sensitive analysis than individual data that can show higher definition. The correlation of individual IgG levels increased with disease severity, reaching an r value of 0.756, but with a high variation between studies. This lack of consistency can be attributed to the neutralisation and ELISA assays used. Neutralisation assay sensitivity varies across the methods and ELISAs are based on different SARS-CoV-2 antigens (e.g. nucleoprotein or spike protein domains), which affect performance [38].

Despite neutralising antibodies not being detectable in a significant proportion of participants, these antibodies are only a visible fraction of the defence mechanism against COVID-19 and second infections are rare and adaptive immunity mechanisms involving B and T cells and mucosal neutralising antibodies are at play [39]. For example, memory B cells display clonal turnover after six months, with maturation of response and expressed antibodies having greater somatic hypermutation, increased potency, and resistance to the Spike protein receptor-binding domain mutations, indicative of a continued evolution of the humoral response [39].

We have examined variations resulting from study settings, testing methodologies, and disease severity and provide an overview based on a large number of studies, resourcing to individual data whenever possible. We have shown that current information is based on a multitude of methods assessing neutralising antibodies, a large variety of ELISAs, including in-house methods without WHO endorsement, and that these differences lead to different proportions of individuals being classified as having positive responses and, possibly, the poor correlation between IgG and neutralising antibodies in aggregated datasets. These limitations highlight the need for standardisation of the methodology and the development of guidelines for future studies. There is a similar a lack of standardisation of objective markers on the assessment of disease severity (e.g., C Reactive Protein) and results are often presented without stratification, which made it difficult to perform meta-regression of subgroups. Moreover, data on circulating SARS-CoV-2 variants, patients’ age, outcome, T cell responses, ELISA’s spike glycoprotein targets, and other potential covariates were not available in significant numbers and there were no studies from South America, the Indian subcontinent, or Africa, and results cannot be generalised to these populations.

In the event of a new pandemic virus there is a limited window where the natural epidemiology of the virus can be observed prior to treatment or vaccination. Without large cohort studies only, a fragmented picture was available, and ongoing cohorts will need to account for virus variants, treatment and vaccination. Combining studies and performing a meta-analysis allowed an analysis of data from early stages and gives a more complete picture of the natural immunity at the beginning of the pandemic.

In conclusion, a high proportion of individuals have evidence of neutralising antibodies after SARS-CoV-2 infection. These proportions vary with disease severity, with asymptomatic infections being less likely to have detectable antibodies than those experiencing severe COVID-19. Most diagnostic tests, therapeutics, and vaccines are aimed at the SARS-CoV-2 Spike, and virus evasion occur through mutations that escape neutralising antibodies. Thus, research is needed to establish whether the lack of detectable neutralising antibodies interrelates with virus escapees with or without a vaccine [40]. This is particularly relevant in light of the recent dominance in parts of the UK of a strain with mutations in the spike protein that is associated with increased transmissibility [41]. Moreover, the minimum level of neutralising antibodies required to achieve protection is unknown at this stage, and immunological memory mechanisms may rapidly boost generation of antibodies that are not detectable in the peripheral blood in the absence of stimulation. This review also highlights the need for guidance on standardised protocols for the measurement of neutralising antibodies; for longitudinal studies to document how neutralising antibodies and their relationship with IgG levels change over time, and whether minimal or undetectable levels indicate lack of clinical protection and thus vulnerability to infection.

Full search strategy.

(DOCX)

Click here for additional data file.

Risk of bias of the studies included using the Quality Assessment Tool for Cohort and Case Series Studies of the National Institutes of Health (NIH).

(DOCX)

Click here for additional data file.

Statistical analysis.

(DOCX)

Click here for additional data file.

23 Apr 2021

Dear Professor Cuevas,

Thank you very much for submitting your manuscript "Prevalence of neutralising antibodies against SARS-CoV-2 in acute infection and convalescence: a systematic review and meta-analysis" for consideration at PLOS Neglected Tropical Diseases. As with all papers reviewed by the journal, your manuscript was reviewed by members of the editorial board and by several independent reviewers. In light of the reviews (below this email), we would like to invite the resubmission of a revised version that takes into account the reviewers' comments.

We cannot make any decision about publication until we have seen the revised manuscript and your response to the reviewers' comments. Your revised manuscript is also likely to be sent to reviewers for further evaluation.

When you are ready to resubmit, please upload the following:

[1] A letter containing a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript. Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

[2] Two versions of the revised manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file).

Important additional instructions are given below your reviewer comments.

Please prepare and submit your revised manuscript within 60 days. If you anticipate any delay, please let us know the expected resubmission date by replying to this email. Please note that revised manuscripts received after the 60-day due date may require evaluation and peer review similar to newly submitted manuscripts.

Thank you again for your submission. We hope that our editorial process has been constructive so far, and we welcome your feedback at any time. Please don't hesitate to contact us if you have any questions or comments.

Sincerely,

Tao Lin, DVM, MSc

Associate Editor

PLOS Neglected Tropical Diseases

Liesl Zuhlke

Deputy Editor

PLOS Neglected Tropical Diseases

***********************

Reviewer's Responses to Questions

Key Review Criteria Required for Acceptance?

As you describe the new analyses required for acceptance, please consider the following:

Methods

-Are the objectives of the study clearly articulated with a clear testable hypothesis stated?

-Is the study design appropriate to address the stated objectives?

-Is the population clearly described and appropriate for the hypothesis being tested?

-Is the sample size sufficient to ensure adequate power to address the hypothesis being tested?

-Were correct statistical analysis used to support conclusions?

-Are there concerns about ethical or regulatory requirements being met?

Reviewer #1: The study is clearly articulated and the objectives well described. The design is appropriately set for a study that is needed in the field. The studies selected are often small and a larger size would benefit however the analysis provides clear conclusions using well established methodology.

--------------------

Results

-Does the analysis presented match the analysis plan?

-Are the results clearly and completely presented?

-Are the figures (Tables, Images) of sufficient quality for clarity?

Reviewer #1: The analysis presented match the analysis plan. The neutralizing antibody results are clearly and well presented.

The IgG analysis comes with a lot of complexity is lacking granularity.

Reviewer #2: (No Response)

--------------------

Conclusions

-Are the conclusions supported by the data presented?

-Are the limitations of analysis clearly described?

-Do the authors discuss how these data can be helpful to advance our understanding of the topic under study?

-Is public health relevance addressed?

Reviewer #1: The conclusions are supported great deal by the data presented and the limitations of analysis are described. The authors discuss how these data are helpful to advance our understanding of the neutralizing antibody immunity against SARS-CoV2. However, larger studies are needed to be able to address the relevance for public health recomendations.

Reviewer #2: (No Response)

--------------------

Editorial and Data Presentation Modifications?

Use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. If the only modifications needed are minor and/or editorial, you may wish to recommend “Minor Revision” or “Accept”.

Reviewer #1: Results

THe IgG/nAntibodie association analysis needs differentiation between different viral antigen or limit it to the surface antigen against which the neutralizing antibodies are directed against.

Discussion

“The lack of neutralising antibodies in a small but significant group of patients might be explained by some patients having responses confined to other SARS-CoV-2 antigens or mediated through T cells, which are not detected by the neutralisation assays in this meta-analysis.” It is not clear who those groups of patients are.

“Mild infections may also elicit responses that are restricted to the mucosal cells, where defence responses are dominated by the secretory immune system.” Interesting statement and good hypothesis that is not evidenced.

“The proportion of participants with neutralising antibodies in the second month was slightly higher among plasma donors and slightly lower among patients recruited from hospital. However, the differences were small and confidence intervals overlapped.

Moreover, neutralising antibodies peak within 21 days after symptoms onset and the one month is not ideal to demonstrate time differences” Do you mean that antibodies in hospitalized individuals might decline faster? Do the responses peak within 21 days for both groups?

Reviewer #2: none

--------------------

Summary and General Comments

Use this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed.

Reviewer #1: The authors describe a meta analysis of published studies describing the neutralising antibody titres induced by SARS-CoV 2 acute infection. This is an important study considering the need to understand corelates of immunity by both infection and vaccination. Furthermore, increasing evidence is arguing for the role of neutralizing antibodies. One element that is clearly understood throughout the study is the lack of large cohort comprehensive studies to establish this fact. Only very few studies could be retained for the analysis amongst large number of publications initially selected. None the less the analysis is well conducted, and the authors conclude that the disease severity is largely correlating with the levels of neutralizing antibodies induced.

There are differences between neutralization assay sensitivity that also show throughout the study and it is unclear to what degree it will affect the analysis.

The authors have investigated the associations between neutralizing antibody titres and the Elisa IgG titres. This part of the study has some weakens as besides the neutralising antibody assay variation the binding antibody assays can also be very variable. The type of assay used and most of all the origin of recombinant antigen utilised will influence the assay a great deal. In addition, table 1 indicates a variety of viral antigens utilised to measure IgG and the study lacks granularity.

Reviewer #2: (No Response)

--------------------

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Figure Files:

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org.

Data Requirements:

Please note that, as a condition of publication, PLOS' data policy requires that you make available all data used to draw the conclusions outlined in your manuscript. Data must be deposited in an appropriate repository, included within the body of the manuscript, or uploaded as supporting information. This includes all numerical values that were used to generate graphs, histograms etc.. For an example see here: http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5.

Reproducibility:

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

Submitted filename: PNTD-D-21-00266 review.docx

Click here for additional data file.

17 May 2021

Submitted filename: Reply_PNTD_R1.docx

Click here for additional data file.

9 Jun 2021

Dear Professor Cuevas,

We are pleased to inform you that your manuscript 'Prevalence of neutralising antibodies against SARS-CoV-2 in acute infection and convalescence: a systematic review and meta-analysis' has been provisionally accepted for publication in PLOS Neglected Tropical Diseases.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

Should you, your institution's press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.

Best regards,

Tao Lin, DVM, MSc

Associate Editor

PLOS Neglected Tropical Diseases

Liesl Zuhlke

Deputy Editor

PLOS Neglected Tropical Diseases

***********************************************************

Reviewer's Responses to Questions

Key Review Criteria Required for Acceptance?

As you describe the new analyses required for acceptance, please consider the following:

Methods

-Are the objectives of the study clearly articulated with a clear testable hypothesis stated?

-Is the study design appropriate to address the stated objectives?

-Is the population clearly described and appropriate for the hypothesis being tested?

-Is the sample size sufficient to ensure adequate power to address the hypothesis being tested?

-Were correct statistical analysis used to support conclusions?

-Are there concerns about ethical or regulatory requirements being met?

Reviewer #2: Yes

**********

Results

-Does the analysis presented match the analysis plan?

-Are the results clearly and completely presented?

-Are the figures (Tables, Images) of sufficient quality for clarity?

Reviewer #2: Yes

**********

Conclusions

-Are the conclusions supported by the data presented?

-Are the limitations of analysis clearly described?

-Do the authors discuss how these data can be helpful to advance our understanding of the topic under study?

-Is public health relevance addressed?

Reviewer #2: Yes

**********

Editorial and Data Presentation Modifications?

Use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. If the only modifications needed are minor and/or editorial, you may wish to recommend “Minor Revision” or “Accept”.

Reviewer #2: (No Response)

**********

Summary and General Comments

Use this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed.

Reviewer #2: (No Response)

**********

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: No

2 Jul 2021

Dear Professor Cuevas,

We are delighted to inform you that your manuscript, "Prevalence of neutralising antibodies against SARS-CoV-2 in acute infection and convalescence: a systematic review and meta-analysis," has been formally accepted for publication in PLOS Neglected Tropical Diseases.

We have now passed your article onto the PLOS Production Department who will complete the rest of the publication process. All authors will receive a confirmation email upon publication.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Editorial, Viewpoint, Symposium, Review, etc...) are generated on a different schedule and may not be made available as quickly.

Soon after your final files are uploaded, the early version of your manuscript will be published online unless you opted out of this process. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.

Best regards,

Shaden Kamhawi

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

Paul Brindley

co-Editor-in-Chief

PLOS Neglected Tropical Diseases